Tirzepatide is not recommended during pregnancy or for people with certain medical conditions, such as thyroid cancer or a history of gastroparesis
This is a harder cutoff than the FDA label (which permits coverage at BMI 30, or 27 with a weight-related comorbidity)
Management that reduces local inflammation, including proper compression, early cold therapy, and graded mobilization, can assist in limiting these signals
If you suspect your constipation is a side effect of your medication, you can report this through the MHRA Yellow Card scheme (yellowcard.mhra.gov.uk or the Yellow Card app)
SM, HK, Y-JK, J-YP, and WL: data interpretation, review, and editing
Cannavo, Salvatore